BioCentury
ARTICLE | Clinical News

Emricasan: Additional Phase II data

May 16, 2016 7:00 AM UTC

Additional data from a U.S. Phase II trial in 86 patients with liver cirrhosis showed that twice-daily 25 mg oral emricasan reduced MELD score by 0.3 points, Child-Pugh score by 0.3 points and total b...